中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

878 records (took 0.06 seconds)

    METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY
    61.
    发明申请
    METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY 审中-公开
    在组合治疗中使用HISTONE脱乙酰壳多糖酶抑制剂和监测生物标志物的方法

    公开(公告)号：WO2008082856A1

    公开(公告)日：2008-07-10

    申请号：PCT/US2007/086874

    申请日：2007-12-07

    Applicant: PHARMACYCLICS, INC. ,  ADIMOOLAM, Shanthi ,  BUGGY, Joseph, J. ,  MAGDA, Darren ,  MILLER, Richard

    Inventor： ADIMOOLAM, Shanthi ,  BUGGY, Joseph, J. ,  MAGDA, Darren ,  MILLER, Richard

    IPC: A61K31/16 ,  A61K31/166 ,  A61P35/00

    CPC classification number: A61K31/164 ,  A61K31/343 ,  A61K31/40 ,  A61K31/4525 ,  A61K45/06 ,  A61K2300/00

    Abstract: Provided herein are methods for using at least one histone deacetylase inhibitor to decrease cellular DNA repair activity, methods for monitoring the decrease of cellular DNA repair activity using at least one biomarker, methods of treating cancer by using at least one histone deacetylase inhibitor to decrease cellular DNA repair activity in combination therapy, methods of combination therapy where at least one histone deacetylase inhibitor interferes with a DNA repairing mechanism involving RAD51, methods for predicting a induction time period between a first administration of at least one histone deacetylase inhibitor and a second administration of at least one other therapeutic treatment, and pharmaceutical compositions for combination therapy.

    Abstract translation: 本文提供了使用至少一种组蛋白脱乙酰酶抑制剂来降低细胞DNA修复活性的方法，使用至少一种生物标志物监测细胞DNA修复活性降低的方法，使用至少一种组蛋白脱乙酰酶抑制剂治疗癌症的方法以减少细胞 联合治疗中的DNA修复活性，其中至少一种组蛋白脱乙酰酶抑制剂干扰涉及RAD51的DNA修复机制的组合疗法的方法，用于预测第一次施用至少一种组蛋白脱乙酰酶抑制剂和第二次给药之间的诱导时间段的方法 至少一种其他治疗性治疗剂，以及用于联合治疗的药物组合物。

    INHIBITORS OF BRUTON'S TYROSINE KINASE
    62.
    发明申请
    INHIBITORS OF BRUTON'S TYROSINE KINASE 审中-公开
    酪氨酸激酶抑制剂

    公开(公告)号：WO2008039218A3

    公开(公告)日：2008-05-29

    申请号：PCT/US2006049626

    申请日：2006-12-28

    Applicant: PHARMACYCLICS INC ,  HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING

    Inventor： HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING

    IPC: A01N43/90 ,  A61K31/519

    CPC classification number: A61K31/52 ,  A61K9/4825 ,  A61K31/00 ,  A61K31/519 ,  A61K39/3955 ,  A61K45/06 ,  C07D487/04 ,  C07K16/2887 ,  C07K2317/24 ,  A61K2300/00

    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

    Abstract translation: 本文公开了与布鲁顿酪氨酸激酶（Btk）形成共价键的化合物。 还描述了Btk的不可逆抑制剂。 公开了制备这些化合物的方法。 还公开了包含该化合物的药物组合物。 单独或与其他治疗剂组合使用Btk抑制剂的方法用于治疗自身免疫疾病或病症，异质性免疫疾病或病症，癌症（包括淋巴瘤）和炎性疾病或病症。

    PROCESS FOR INHIBITING CELL PROLIFERATION
    68.
    发明申请
    PROCESS FOR INHIBITING CELL PROLIFERATION 审中-公开
    抑制细胞增殖的方法

    公开(公告)号：WO2005085254A1

    公开(公告)日：2005-09-15

    申请号：PCT/US2005/006278

    申请日：2005-03-01

    Applicant: PHARMACYCLICS, INC. ,  MAGDA, Darren

    Inventor： MAGDA, Darren

    IPC: C07D487/22

    CPC classification number: A61K31/315 ,  A61K33/24 ,  A61K45/06

    Abstract: The present invention relates to a process of inhibiting proliferation of neoplastic cells in a host, said process comprising administering to the host: (a) a zinc reagent and (b) a compound of Formula (I) wherein M is selected from Gd +++ . EU +++ . Tb+++. ' [)"++. ~~O +++ and Er +++ .

    Abstract translation: 本发明涉及一种抑制宿主中肿瘤细胞增殖的方法，所述方法包括对宿主施用：（a）锌试剂和（b）式（I）化合物，其中M选自Gd + ++>。<> EU <+++>。<> Tb +++。 '[）“++。~~ O <+++>和Er <+++>。

    PROCESS FOR AFFECTING NEUROLOGIC PROGRESSION
    69.
    发明申请
    PROCESS FOR AFFECTING NEUROLOGIC PROGRESSION 审中-公开
    影响神经病学进展的过程

    公开(公告)号：WO2003049731A1

    公开(公告)日：2003-06-19

    申请号：PCT/US2002/039974

    申请日：2002-12-12

    Applicant: PHARMACYCLICS, INC ,  MILLER, Richard, A.

    Inventor： MILLER, Richard, A.

    IPC: A61K31/33

    CPC classification number: A61K31/555 ,  A61K47/546 ,  A61K47/60

    Abstract: The present invention relates to use of a compound of Formula I : for improving neurologic functions in patients afflicted with systemic lung cancer that has metastasized to the brain (brain metastases).

    Abstract translation: 本发明涉及式I化合物用于改善患有转移至脑的全身性肺癌（脑转移）的患者的神经功能。

    COMPOSITIONS FOR TREATING ATHEROMA AND NEOPLASTIC TISSUE
    70.
    发明申请
    COMPOSITIONS FOR TREATING ATHEROMA AND NEOPLASTIC TISSUE 审中-公开
    用于治疗甲状腺和神经组织的组合物

    公开(公告)号：WO0132210A3

    公开(公告)日：2002-02-07

    申请号：PCT/US0029515

    申请日：2000-10-27

    Applicant: PHARMACYCLICS INC ,  UNIV TEXAS ,  SESSLER JONATHAN L ,  MADGA DARREN

    Inventor： SESSLER JONATHAN L ,  MADGA DARREN

    IPC: A61K31/555 ,  A61K41/00 ,  A61K49/00

    CPC classification number: A61K9/0019 ,  A61K41/0038 ,  A61K49/0004 ,  G01N33/5008

    Abstract: The radiation sensitization potential of a candidate compound can be screened by determining its ability to generate one or more reactive oxygen species under appropriate conditions. Compounds determined to have radiation sensitization potential are employed in methods for treating atheroma, tumors and other neoplastic tissue as well as other conditions that are typically responsive to radiation sensitization.

    Abstract translation: 候选化合物的辐射致敏电位可以通过确定其在合适条件下产生一种或多种活性氧物质的能力进行筛选。 被确定为具有辐射敏化潜能的化合物用于治疗动脉粥样化，肿瘤和其它肿瘤组织以及通常对辐射敏化反应的其它病症的方法。

Patent Agency Ranking